1-3 of 3
Junji Tanaka
Close
Sort by
Journal Articles

CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia

Clinical Trials & Observations
Yu Akahoshi, Hideki Nakasone, Katsuto Takenaka, Satoshi Yamasaki, Momoko Nakamura, Noriko Doki, Masatsugu Tanaka, Yukiyasu Ozawa, Naoyuki Uchida, Takahide Ara, Hirohisa Nakamae, Shuichi Ota, Makoto Onizuka, Shingo Yano, Junji Tanaka, Takahiro Fukuda, Yoshinobu Kanda, Yoshiko Atsuta, Shinichi Kako, Masamitsu Yanada, Yasuyuki Arai
Journal: Blood Advances
Blood Adv (2023) 7 (12): 2699–2708.
https://doi.org/10.1182/bloodadvances.2022009376
Published: 2023
Includes: Supplemental data
Journal Articles

Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades

Clinical Trials & Observations
Satoshi Nishiwaki, Yu Akahoshi, Mari Morita-Fujita, Hiroaki Shimizu, Naoyuki Uchida, Yukiyasu Ozawa, Takahiro Fukuda, Masatsugu Tanaka, Kazuhiro Ikegame, Shuichi Ota, Yuta Katayama, Satoshi Takahashi, Toshiro Kawakita, Takahide Ara, Makoto Onizuka, Takafumi Kimura, Junji Tanaka, Yoshiko Atsuta, Yasuyuki Arai
Journal: Blood Advances
Blood Adv (2022) 6 (15): 4558–4569.
https://doi.org/10.1182/bloodadvances.2022008032
Published: 2022
Includes: Supplemental data
Journal Articles

Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph + ALL during both CR1 and CR2

Clinical Trials & Observations
Satoshi Nishiwaki, Yu Akahoshi, Shuichi Mizuta, Akihito Shinohara, Shigeki Hirabayashi, Yuma Noguchi, Takahiro Fukuda, Naoyuki Uchida, Masatsugu Tanaka, Makoto Onizuka, Yukiyasu Ozawa, Shuichi Ota, Souichi Shiratori, Yasushi Onishi, Yoshinobu Kanda, Masashi Sawa, Junji Tanaka, Yoshiko Atsuta, Shinichi Kako
Journal: Blood Advances
Blood Adv (2021) 5 (2): 584–592.
https://doi.org/10.1182/bloodadvances.2020003536
Published: 2021